Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients

Arch Gen Psychiatry. 1992 Aug;49(8):643-9. doi: 10.1001/archpsyc.1992.01820080051008.

Abstract

We examined the state-dependent contribution of neuroleptic withdrawal and psychotic relapse in influencing sleep measures. Eighteen clinically stable male schizophrenic patients taking haloperidol were studied with 3 nights of polysomnography for baseline measures and again after neuroleptic withdrawal. Sleep measures were also obtained at the point of relapse (n = 9) or after a 6-week drug-free period if the patient remained clinically stable (n = 9). Neuroleptic withdrawal led to a global deterioration of rapid eye movement and non-rapid eye movement sleep and a reduction of rapid eye movement latency in both groups. Relapsers differed from nonrelapsers in that they had a larger decrease in total sleep time, sleep efficiency, total non-rapid eye movement sleep, and stage 2 sleep. The level of psychosis was inversely correlated with sleep efficiency, total sleep time, and stage 4 sleep in the drug-free patients. Our data suggest that clinical state needs to be identified in sleep studies of drug-free patients.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Delta Rhythm
  • Electroencephalography / drug effects
  • Female
  • Haloperidol / administration & dosage*
  • Haloperidol / adverse effects
  • Haloperidol / pharmacology
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Schizophrenia / drug therapy
  • Schizophrenia / physiopathology*
  • Schizophrenic Psychology
  • Sleep / drug effects
  • Sleep / physiology*
  • Sleep Stages / drug effects
  • Sleep Stages / physiology
  • Sleep, REM / drug effects
  • Sleep, REM / physiology
  • Substance Withdrawal Syndrome / etiology*

Substances

  • Haloperidol